HCV patients treated with sofosbuvir maintained high SVR despite negative predictors
May 13, 2014
CHICAGO — Hepatitis C virus-infected patients with genotypes 1, 2 or 3 displayed high sustained virologic response rates after being treated with a sofosbuvir-based regimen despite the presence of negative predictors, according to data presented at Digestive Disease Week 2014.
Ira M. Jacobson, MD, chief of the division of gastroenterology and hepatology at Weill Cornell Medical College, New York, and co-chief medical editor of HCV Next, and colleagues performed univariate and multivariate regression analyses on 868 treatment-naive patients. The study included 339 patients with genotype 1 who received sofosbuvir (SOF) with pegylated interferon alfa plus ribavirin (PegIFN/RBV) for 12 weeks, 285 with genotype 2 who were treated with SOF with RBV for 12 weeks, and 244 genotype 3 patients who received 24 weeks SOF with RBV. Researchers sought to identify variables that may be associated with relapse and affected sustained virologic response (SVR) rates.
Full Story »
No comments:
Post a Comment